Just to make it also clear they have Russian approval. Statistically from what I remember reading there are 10 million liver degenerative cases in Russia at present with a million or so being added annually. Do the mathematics. Numerous Russian hospitals have already indicated that they wish to use Ropren. It wouldn't even hurt the Company if Ropren wasn't available here! The Russian side alone is enough to catapult the share price well above current levels. The Russians believe in the product which is substantially cheaper than current products with none of the side effects. SLA from what was relayed at the meeting and what was contained within the presentation appear to be targeting European interests anyway at this stage. Once they get the European funds on board etc watch out!
SLA Price at posting:
45.7¢ Sentiment: LT Buy Disclosure: Held
